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Background: Reports dealing with clinical outcomes of classical Hodgkin’s lymphoma in low-
to  middle-income countries are scarce and response to therapy is poorly documented.
This report describes the characteristics and clinical outcomes of patients with classical
Hodgkin’s lymphoma from a single institution in Latin America.
Method: A retrospective study was conducted over ten years of patients with classical
Hodgkin’s lymphoma treated at a referral center. Progression-free and overall survival rates
were  estimated by Kaplan–Meier analysis. The univariate Cox regression model was used
to  estimate associations between important variables and clinical outcomes.
Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5
years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively.
Of  the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with
advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remis-
sion.  Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for
early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received
a  transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355
(p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin’s lymphoma patients
diagnosed at advanced stages had a low progression-free survival but an overall survivalsimilar to high-income countries.
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Conclusion: Patients belonging to the general population diagnosed with classical Hodgkin’s
lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and
presented with advanced disease, underscoring the need for earlier diagnosis and improved
contemporary therapeutic strategies in these mainly young productive-age Hodgkin’s lym-
phoma patients.
© 2017 Published by Elsevier Editora Ltda. on behalf of Associação Brasileira de
Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC
Y-NCB
Introduction
Hodgkin’s lymphoma (HL) is one of the most common malig-
nancies in the young population; it has a bimodal distribution,
first between 15 and 34 years of age and then after 55 years.1
This hematologic neoplasm affects approximately 9050 new
patients in the United States each year and 5000 in Latin
America,2 thus a low incidence but with high mortality is
observed in Mexico.3 Furthermore, a lower overall survival (OS)
has been observed in Hispanics living in the United States,
with the diagnosis established at more  advanced stages and
with a greater male prevalence.4,5
Contrary to non-Hodgkin lymphoma, the incidence of
HL has remained constant over time.1 Two distinct disease
entities compose HL, classical (cHL) and the rare nodular lym-
phocyte predominant HL, which comprises only 5% of all
cases.6 Although HL is highly responsive to chemotherapy,
approximately one third of patients with an advanced stage
will have primary resistant disease7 or will relapse after con-
ventional treatment.8 Standard treatment in these cases is
based on autologous hematopoietic stem cell transplantation
(HSCT) or high doses of chemotherapy, with the PFS reach-
ing 30–50% in patients with relapsed disease and 20–40% in
patients with refractory HL.9–11
There is scarce information on the characteristics of HL
patients in populations where most individuals are diag-
nosed in advanced stages. This study reports a comprehensive
descriptive analysis of incidence patterns, clinical evolution,
and treatment outcomes of low-income uninsured patients
with HL attending a public referral center for the general pop-
ulation in Northeastern Mexico over a ten-year period.
Methods
This observational, longitudinal and retrospective study
included patients with a diagnosis of HL treated at the Hema-
tology Department of the Dr. José E. González University
Hospital of the School of Medicine, Universidad Autónoma
de Nuevo León in Monterrey, Mexico between January 2005
and September 2015. Clinical and electronic records as well
as histopathology records were reviewed and frequencies for
each subtype of lymphoma were determined. The study pro-
tocol was approved by the Research Ethics Committee of the
institution.
Clinical data including age, gender, Ann Arbor stage,
presence or absence of B-symptoms, initial complete blood
count (CBC), International Prognostic Score (IPS), bulky dis--ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ease, treatment regimen and survival data were accrued
and analyzed. Advanced disease was defined as bulky dis-
ease or an Ann Arbor stage III–IV. Two groups were defined
according to the IPS: low risk (score: 0–3) and high risk
(score: 4–7). To define HL subtypes, cases were reviewed by
a hematopathologist with the immunohistochemical pro-
file of HL being investigated in 83% of the studied patients
including the following biomarkers: CD30, CD15, CD20, CD3,
CD45, ALK-1, and PAX-5.12 Due to financial restrictions at this
public institution caring for patients without health insur-
ance coverage, the Epstein–Barr virus (EBV) status was not
documented in the biopsies. A computed tomography (CT)
scan was performed in all patients for stratification and
was reviewed by radiologists with expertise in staging lym-
phomas. Only selected patients were submitted to a bone
marrow (BM) biopsy – patients with an Ann Arbor stage ≥III
or with B-symptoms had an indication for this procedure. In
this respect, it has previously been shown that only about
2% of patients in this population with HL have a positive
BM biopsy.13
Treatment
Patients received a chemotherapy regimen chosen by the
treating physician according to standard protocols including
ABVD (adriamycin, bleomycin, vincristine and dacarbazine)
or COPP/ABV (cyclophosphamide, vincristine, prednisone,
procarbazine, doxorubicin, bleomycin and vinblastine).14 All
drugs were from original manufacturers with no generic
brands administered. Some patients with bulky disease
received complementary radiotherapy (RT), using intensity-
modulated radiotherapy (IMRT) at doses of 30–36 Gy depend-
ing on the tumor size. The protocol consists of the delivery
of 1.5–2 Gy per day until completion.15 However, not all of
these patients were treated at the study center and radio-
therapy is not a regular part of the standard protocol; this
is intended to limit radio-toxicity in patients customarily
presenting with advanced disease. Autologous HSCT, based
on a reduced intensity conditioning regimen,16 was carried
out in patients with a poor prognosis, including those who
relapsed in <12 months, those who relapsed at previously
irradiated sites, had disease regression <50% after 4–6 cycles
of chemotherapy, or disease progression during induction or
within 90 days after the end of first-line treatment.
Follow-upPositron emission tomography (PET) studies were not avail-
able during the study period and thus classification of HL
er. 2 0 1 7;3  9(4):325–330 327
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Table 1 – Epidemiological and clinical characteristics of
128 patients diagnosed with Hodgkin’s lymphoma in the
Hospital Universitario Dr. José E. González, Universidad
Autónoma de Nuevo León, Monterrey, Mexico.
Characteristic
Age (years) – median (range) 28.5 (5–81)
Sex – n (%)
Male 69 (53.9%)
Female 59 (46.1%)
Bulky disease – n (%)
Present 27 (21.1%)
Absent 101 (78.9%)
Subtype – n (%)
Nodular sclerosis 75  (58.6)
Mixed cellularity 23 (18.0)
Lymphocyte-rich 5 (3.9)
Lymphocyte depleted 3 (2.3)
Unclassified 22 (17.2)
Clinical stage – n (%)
I 16 (11.7)
II 38 (29.7)
III 35 (27.3)
IV 40 (31.3)
IPS score – n (%)
0–3 98 (76.6)
4–7 30 (23.4)
Disease status – n (%)
Early disease 45 (35.2)rev bras hematol hemot
esponse was according to the criteria specified in the Lugano
lassification,17 based on size reduction of the affected lymph
odes measured by CT scan in all patients.
efinition  of  response
R was defined as disappearance of all clinical and radiological
ymptoms, no further therapeutic intervention is necessary.
artial remission (PR) was defined as at least a 50% decrease
n the sum of the product of the diameters of up to six of
he largest dominant nodes or nodal masses. Stable disease
as considered when a patient failed to meet the criteria
or CR or PR, but did not fulfill those for progressive disease
PD). Relapsed disease or PD was defined as the occurrence of
ew lesions or an increase of ≥50% from nadir of previously
nvolved sites.17
tatistical  analysis
ll statistical testing was performed using SPSS version 22.0.
escriptive analysis including median and ranges was applied
o continuous variables. The Kaplan–Meier method was used
o obtain the OS from the date of diagnosis until the date of
eath or last update of clinical status. PFS was defined from
he date of diagnosis to the date of the first event (progres-
ion/relapse or death for any reason) or the last follow-up.17
he Cox proportional hazard regression model was used to
xamine the association between the different variables and
heir effect on OS and PFS in HL.
esults
aseline  characteristics
ata for 128 patients with a diagnosis of HL were collected.
linical characteristics are shown in Table 1. B-symptoms
ere reported by 45 (35.1%) patients at the time of initial
linical history. Complete blood count (CBC) at diagnosis
howed a median hemoglobin (Hb) level of 11.4 g/dL (range:
.9–17 g/dL), a white blood cell count of 8.29 × 109/L (range:
.11–25.57 × 109/L) and a platelet count of 308 × 109/L (range:
1.0–629.0 × 109/L). Bone marrow biopsy was performed in 46
35.9%) patients in advanced stages with a positive result being
ound in 14 (30.4%).
linical  outcome  in  classical  Hodgkin’s  lymphoma
ne hundred and twenty-eight patients were analyzed, 112
87.5%) received ABVD (median: 6 cycles; range: 1–8 cycles) and
6 (12.5%) received the COPP/ABV regimen (median: 6 cycles;
ange: 2–8 cycles). CR was achieved in 73/128 (57%) patients;
0/73 (41%) relapsed at a median of 23.7 months. From the
roup of 30 relapsed patients, 26 (86.7%) are alive after five
ears of follow-up and four deaths have been documented. Of
he whole group, 55 (43%) were primary refractory cases; from
his subgroup 20 (36.4%) had partial remission, 29 (52.7%) sta-
le disease after first frontline chemotherapy, and six (10.9%)
resented disease progression during administration of the
rimary therapy protocol. Eleven deaths (7.75%) were docu-Advanced disease 83 (64.8)
IPS: International Prognostic Score.
mented after receiving at least one cycle of chemotherapy
with sepsis being the most common cause. Twenty-two (17.2%)
patients who completed therapy as scheduled had a reduc-
tion in dose due to toxicity. Twenty-eight (21.87%) patients
did not complete planned treatment with the most common
cause being disease progression in 19, whereas nine patients
abandoned treatment. Six patients that abandoned treatment
went on to continue chemotherapy in other institutions; three
patients were too sick to receive full doses and cycles of ther-
apy. There were no instances of missing drugs.
Median follow-ups for PFS and OS were 15.88 (range
1.2–87.8) and 24.26 (range 1.43–176) months, respectively.
PFS at five years for the whole group of 128 patients was
37.3 ± 6.9%. Median PFS at five years was 46.09 months [95%
confidence interval (CI): 34.06–58.12]. After five years of follow-
up, the OS was 78.9 ± 6.8% and the median OS was not reached.
Patients who achieved CR with first line treatment had a five-
year OS of 88.1 ± 6.3% vs. 59 ± 15.7%, in those who did not
(p-value = 0.012).
Of 11 patients who died, two did so from sepsis and neu-
tropenia related to drug toxicity and in seven, death was due
to disease progression; two patients died at other institutions
and the cause was not reported.
When comparing chemotherapy regimens, the five-year
PFS for patients treated with ABVD was 37.5 ± 7.9% vs.
33.5 ± 13.9% for those who received a different scheme (p-
value = 0.224). Five-year OS for patients primarily treated with
ABVD was 81.5 ± 7.7% vs. 63.1 ± 15.8% for those receiving
oter. 2 0 1 7;3  9(4):325–330
Table 2 – Hazard ratios for relapse, progression or death
according to univariate Cox proportional regression
analysis for 128 patients with classical Hodgkin’s
lymphoma and associations with clinical, laboratory
and histopathological characteristics.
Factor n Progression free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Bulky disease
Present 27 0.965
(0.458–2.030)
0.925 0.812
(0.161–4.095)
0.801
Absent 71
IPS
≥4 30 0.912
(0.439–1.895)
0.805 3.355
(1.000–11.256)
0.050
<4 98
Bone marrow infiltration
Positive 14 2.628
(1.058–6.525)
0.037 4.511
(0.408–49.863)
0.219
Negative 32
B-symptoms
Yes 41 0.672
(0.358–1.263)
0.217 0.384
(0.083–1.789)
0.222
No 87
Incomplete treatment
Yes 28 2.793
(1.364–5.719)
0.005 8.246
(2.483–27.377)
0.001
No 100328  rev bras hematol hem
COPP/ABV (p-value = 0.057). Median time to receive six cycles
of therapy was six months (range: 6–9 months).
Of the patients with advanced disease, a CR was reached
in 39/83 (47%) vs. 34/45 (75.6%) in those in early HL stages
(p-value = 0.002). Five-year PFS for patients presenting with
advanced disease was 38.3 ± 8.9% vs. 39.1 ± 11.5% in indi-
viduals with early disease (p-value = 0.893). Median PFS for
advanced and early disease was 42.7 months (95% CI
27.51–57.90) and 49.5 months (95% CI 39.28–59.81), respec-
tively. Overall survival at five years was 69.7 ± 10.6% in patients
with advanced disease compared to 91.8 ± 5.6% in those with
early disease (p-value = 0.132; data not shown). Median OS was
not reached in either group.
Fifteen pediatric HL patients (11.7%) ≤16 years and 113
(88.3%) >16 years were treated. PFS at five years was higher
in those >16 years of age, but it was not statistically signifi-
cant (20.9 ± 12.9% vs. 36.0 ± 8.4%, respectively), median of PFS
was 34.72 months (95% CI 16.59–52.86) vs. 48 months (95%
CI 37.41–58.59; p = 0.240), respectively. Pediatric patients had
a non-significantly higher five-year OS than older patients
(80.0 ± 12.6% vs. 76.2 ± 9.3%; p-value = 0.871). After analyzing
survival according to the IPS, patients with a score ≥4 had a
five-year PFS of 33.7 ± 14.9% vs. 34.9 ± 8.4% in those with an
IPS <4 (p-value = 0.786). The five-year OS between these groups
was 66.1 ± 13.8% vs. 84.1 ± 7.1%, respectively (p-value = 0.036).
Thirty-two patients (25%) underwent autologous HSCT,
achieving a five-year PFS of 32.6% (95% CI: 32.40–32.80) after
HSCT at a median of 20 months and the five-year OS was
73.1%; the median OS was not reached. Of the 32 autografted
patients, six (18.8%) deaths were documented and 15 (46.9%)
suffered disease progression or relapsed after HSCT.
Outcome  after  relapse
Of 30 relapsed patients, 20 (66.7%) underwent autologous
HSCT and 11 (55%) suffered a second relapse. Five-year PFS and
OS for these 20 HSCT patients were 31.4 ± 9.1% and 81.4 ± 9.7%,
respectively; median PFS was 12 months and the median
OS was not reached. Three deaths were documented in this
group due to disease progression. Of the remaining 10 relapsed
patients who were not transplanted, two went to another
institution after relapse and eight were lost to follow-up after
a median 6.4 months.
Predictive  factors  of  relapse,  progression  and  death
In univariate analysis for PFS, BM infiltration and incomplete
treatment were significant for disease progression (Table 2).
For OS, an IPS ≥4 and incomplete treatment were significant
predictors of death (Table 2).
Discussion
Although recent research has provided meaningful insights
into the biological and molecular characteristics of HL, it
remains an intriguing disease, with many  factors implicated
in its pathogenesis but with none definitely established.18 Pre-
vious epidemiologic studies have contributed in elucidating
specific features and current status of HL in the Americas.3HR: hazard ratio; CI: confidence interval; IPS: International Prognos-
tic Score.
Subtype distribution in this group was similar to that in the
United States and Canada.19 Interestingly, the HL cohort in this
study was a decade younger than that reported in developed
countries1,2 as observed in a previous all-age inclusive study
focused on Hispanics.20
In low- to middle-income countries, more  than 60% of
cHL patients are diagnosed in advanced clinical stages at
presentation.21 Progress in survival is evident in those with
early stages, whereas in advanced disease an unsubstantial
improvement has been reported in the last 30 years.22 This
study found an OS close to that reported by centers in devel-
oped countries, yet a low PFS, highlighting the lower cure rate
for advanced disease.23 A higher PFS was found in central
Mexico than that identified in this study; however, OS was
similar,21 showing regional differences in the clinical course
of HL.
In previous studies from high-income countries including
the United States and Europe, CR and OS rates of up to 80%
were reported in patients with advanced clinical stages at
diagnosis.23–25 However, low CR and OS rates were found for
the population with advanced disease in the current study;
only 47% achieved CR after primary treatment, their five-
year PFS was 38.3% with an OS of 68.7%. The high rate of
primary refractory disease and low PFS in this group can
to be explained in part by the large proportion of advanced
er. 2 0
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tage cases related to late diagnosis, biologic heterogeneity
n lymphoma behavior, as well as epigenetic modifiers of
esponse to cHL. Additional factors that can contribute to fur-
her explain these suboptimal results include dose reductions
ue to high toxicity in 22% of patients, treatment aban-
onment was important at 7%, and sociocultural as well as
nancial limitations of this population. Furthermore, lack
f fluorodeoxyglucose (FDG)-PET studies could have led to
ower intensity treatment, although there are heterogeneous
esults regarding the impact of interim FDG-PET; its use how-
ver is a valuable method for risk stratification.17 Developing
ountries are just starting to use this resource due to its high
ost, limiting comparison of treatment response rates for HL
etween developing and industrialized regions.
Over a third of the patients in this study had primary refrac-
ory disease, more  than two times the 15% reported in most
tudies1,8; this finding helps to explain the low PFS observed.
or this group, high-dose chemotherapy followed by autolo-
ous HSCT has become the treatment of choice.26,27 This leads
o a significant increase in PFS, but has no effect on OS. Of
0 relapsed patients in this study, 20 underwent an autol-
gous HSCT after achieving a second remission induced by
hemotherapy and 85% of them are alive at five years. Thus,
he OS after transplantation is comparable to other studies
eporting rates ranging from 66% to 77%.28
The prognosis of relapsed patients is also influenced by
he presence of negative prognostic risk factors such as early
elapse three to 12 months after treatment, stage III or IV
isease, and anemia at the time of relapse. A retrospective
nalysis of the German Hodgkin Study Group showed that
atients presenting all three risk factors had a lower four-year
reedom from second treatment failure of 17% and a low OS of
7% compared to patients without risk factors (48% and 83%,
espectively).29 Although most of the patients in this cohort
ere diagnosed at an advanced stage, the median of relapse
as 22.8 months and this was associated with high survival
ates after relapse.
Limitations in this report include its retrospective design,
educed sample size, lack of PET scan staging, and the
umber of patients lost to follow-up. However, this report pro-
ides an overview of the contemporary landscape of clinical
nd histopathology characteristics of a well-defined HL low-
ncome group over ten years in a single institution of Latin
merica.
In conclusion, it is necessary to analyze cHL epidemiologi-
al data in developing countries and assess efficacy of current
iagnostic methods and modalities of treatment, with the
ain goal of improving the low PFS documented in this pop-
lation.
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